Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Usefulness of Enzyme-Linked Immunospot Assay (Elispot) Compared to Tuberculin Skin Testing for Latent Tuberculosis Screening in Rheumatic Patients Scheduled for Anti-Tumor Necrosis Factor Treatment

DIMITRIOS VASSILOPOULOS, NIKOLAOS STAMOULIS, EMILIA HADZIYANNIS and ATHANASIOS J. ARCHIMANDRITIS
The Journal of Rheumatology July 2008, 35 (7) 1271-1276;
DIMITRIOS VASSILOPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dvassilop@med.uoa.gr
NIKOLAOS STAMOULIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EMILIA HADZIYANNIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATHANASIOS J. ARCHIMANDRITIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective

Treatment with tumor necrosis factor (TNF) antagonists in patients with rheumatic diseases has been associated with increased rates of tuberculosis due to reactivation of latent Mycobacterium tuberculosis (MTb) infection (LTBI). Diagnosis of LTBI is based mainly on the tuberculin skin test (TST), which has certain limitations.

Methods

We compared the TST with an enzyme-linked immunospot interferon-γ (IFN-γ) release assay (Elispot; T SPOT® TB) for the diagnosis of LTBI in 70 patients with various rheumatic diseases starting treatment with anti-TNF agents. All patients underwent a standard initial evaluation for LTBI including clinical examination, chest radiograph, and standard TST. Freshly isolated peripheral blood mononuclear cells were stimulated ex vivo with MTb-specific antigens (ESAT-6 and CFP10), and IFN-γ-producing cells were counted (Elispot assay).

Results

Twenty-seven patients (38.6%) were TST+ and 16 were Elispot+ (22.8%). The overall level of agreement between the 2 tests was 72.8%, being much higher in patients who were TST− (39/43, 90.6%) than in those who were TST+ (12/27, 44.4%). Discordant results were observed in 19 patients (27.1%). Among TST− patients (n = 43), 4 were Elispot+ (9.3%); we also identified 15 Elispot− patients among 27 TST+ patients (55.6%). Multivariate analysis showed that a history of bacillus Calmette-Guérin (BCG) vaccination was associated with TST+/Elispot− discordant results (p = 0.01), whereas steroid use was linked to TST−/Elispot+ discordant results (p = 0.04).

Conclusion

Elispot assay is a useful test for diagnosis of LTBI in rheumatic patients scheduled for anti-TNF therapy and identification of patients with false-positive TST results due to previous BCG vaccination.

Key Indexing Terms:
  • TUMOR NECROSIS FACTOR INHIBITORS
  • RHEUMATOID ARTHRITIS
  • TUBERCULOSIS
  • SPONDYLOARTHROPATHIES
  • TUBERCULIN TEST
  • DIAGNOSIS

Footnotes

  • D. Vassilopoulos, MD, Assistant Professor of Medicine, Rheumatology; N. Stamoulis, MD; E. Hadziyannis, MD, Instructor in Clinical Microbiology; A.J. Archimandritis, MD, Professor of Medicine, Chairman, 2nd Department of Medicine, Hippokration General Hospital, Athens University School of Medicine.

    • Accepted for publication December 6, 2007.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 35, Issue 7
1 Jul 2008
  • Table of Contents
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Usefulness of Enzyme-Linked Immunospot Assay (Elispot) Compared to Tuberculin Skin Testing for Latent Tuberculosis Screening in Rheumatic Patients Scheduled for Anti-Tumor Necrosis Factor Treatment
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Usefulness of Enzyme-Linked Immunospot Assay (Elispot) Compared to Tuberculin Skin Testing for Latent Tuberculosis Screening in Rheumatic Patients Scheduled for Anti-Tumor Necrosis Factor Treatment
DIMITRIOS VASSILOPOULOS, NIKOLAOS STAMOULIS, EMILIA HADZIYANNIS, ATHANASIOS J. ARCHIMANDRITIS
The Journal of Rheumatology Jul 2008, 35 (7) 1271-1276;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Usefulness of Enzyme-Linked Immunospot Assay (Elispot) Compared to Tuberculin Skin Testing for Latent Tuberculosis Screening in Rheumatic Patients Scheduled for Anti-Tumor Necrosis Factor Treatment
DIMITRIOS VASSILOPOULOS, NIKOLAOS STAMOULIS, EMILIA HADZIYANNIS, ATHANASIOS J. ARCHIMANDRITIS
The Journal of Rheumatology Jul 2008, 35 (7) 1271-1276;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • The Association of Illness-related Uncertainty With Mental Health in Systemic Autoimmune Rheumatic Diseases
Show more Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire